ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1490

Cardiovascular Morbidity and Mortality in Primary Sjögren Syndrome: A Systematic Review and Meta-Analysis

Aurélie Beltai1, Cédric Lukas2, Cécile Gaujoux-Viala3, Bernard Combe4, Jacques Morel4 and Thomas Barnetche5, 1Department of rheumatology, Teaching hospital Lapeyronie and University of Montpellier, Montpellier, France, 2Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, 3Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, 4Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, 5Rheumatology, CHU Pellegrin, Bordeaux, France, Bordeaux, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Sjogren's syndrome and cardiovascular disease

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Sjögren's Syndrome Poster II: Clinical Research

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: It is well documented that patients with immune-mediated inflammatory diseases (IMID) like rheumatoid arthritis are exposed at an increased risk of cardiovascular disease. Primary Sjögren syndrome (PJS) is a progressive autoimmune disease characterized by a chronic inflammation of exocrine glands and a functional deficit of the salivary and lachrymal glands, biological inflammation being infrequent. The purpose of this article was to investigate the association between PJS and an increase of the cardiovascular morbidity and mortality.

Methods: We performed a systematic review of available articles on the databases of MEDLINE and the COCHRANE library from their dates of inception to January 2017 and recent abstracts from ACR and EULAR meetings, searching for studies reporting observed cardiovascular morbidity and cardiovascular mortality in PJS and having a comparison group. The relative risks of cardiovascular morbidity and mortality associated with PJS were collected and pooled in meta-analysis using Review Manager Software (Cochrane collaboration). Random effects meta-analyses were conducted, and forest plots were constructed to summarize the risk ratio estimates and their 95% confidence intervals. The heterogeneity between studies was assessed using the Cochran’s Q-test and the I2 value.

Results: 457 studies were retrieved, among which 26 involving 61254 PJS patients met the inclusion criteria and were analyzed after the selection procedure was applied. Ten studies involving 32 907 PJS patients were included in the meta-analysis. The studies showed that patients with PJS had a significantly increased prevalence of coronary morbidity (relative risk (RR)= 1.75, 95%CI : 1.36-2.25; p<0.0001), cerebrovascular morbidity (RR= 1.46, 95%CI : 1.43-1.49, p<0.00001), heart failure rate (odd ratio (OR)=2.54, 95%CI: 1.30 – 4.97, p<0.007), thromboembolic morbidity ( RR= 1.78, 95% confidence interval (CI) :1.41- 2.25, p<0.00001), and a trend to increased cardiovascular mortality ((RR)= 1.48, 95%CI : 0.77-2.85, p=0.24) compared to the control population without IMID.

Conclusion: This meta-analysis demonstrates that PJS is associated with an increased cardiovascular morbidity suggesting that these patients should also been proposed for a screening of cardiovascular comorbidities and specific preventive interventions.


Disclosure: A. Beltai, None; C. Lukas, None; C. Gaujoux-Viala, None; B. Combe, None; J. Morel, None; T. Barnetche, None.

To cite this abstract in AMA style:

Beltai A, Lukas C, Gaujoux-Viala C, Combe B, Morel J, Barnetche T. Cardiovascular Morbidity and Mortality in Primary Sjögren Syndrome: A Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/cardiovascular-morbidity-and-mortality-in-primary-sjogren-syndrome-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cardiovascular-morbidity-and-mortality-in-primary-sjogren-syndrome-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology